BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 19836232)

  • 1. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
    Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-Fluorocytosine derivatives as inhibitors of deoxycytidine kinase.
    Tarver JE; Jessop TC; Carlsen M; Augeri DJ; Fu Q; Healy JP; Heim-Riether A; Xu A; Taylor JA; Shen M; Keyes PE; David Kimball S; Yu XC; Miranda M; Liu Q; Swaffield JC; Nouraldeen A; Wilson AG; Finch R; Jhaver K; Foushee AM; Anderson S; Oravecz T; Carson KG
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6780-3. PubMed ID: 19836229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
    Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
    J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
    Wang T; Lamb ML; Scott DA; Wang H; Block MH; Lyne PD; Lee JW; Davies AM; Zhang HJ; Zhu Y; Gu F; Han Y; Wang B; Mohr PJ; Kaus RJ; Josey JA; Hoffmann E; Thress K; Macintyre T; Wang H; Omer CA; Yu D
    J Med Chem; 2008 Aug; 51(15):4672-84. PubMed ID: 18646745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
    Cole DC; Asselin M; Brennan A; Czerwinski R; Ellingboe JW; Fitz L; Greco R; Huang X; Joseph-McCarthy D; Kelly MF; Kirisits M; Lee J; Li Y; Morgan P; Stock JR; Tsao DH; Wissner A; Yang X; Chaudhary D
    J Med Chem; 2008 Oct; 51(19):5958-63. PubMed ID: 18783200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
    Abraham S; Hadd MJ; Tran L; Vickers T; Sindac J; Milanov ZV; Holladay MW; Bhagwat SS; Hua H; Ford Pulido JM; Cramer MD; Gitnick D; James J; Dao A; Belli B; Armstrong RC; Treiber DK; Liu G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5296-300. PubMed ID: 21802948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
    Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent and selective thienopyrimidine inhibitors of Aurora kinases.
    McClellan WJ; Dai Y; Abad-Zapatero C; Albert DH; Bouska JJ; Glaser KB; Magoc TJ; Marcotte PA; Osterling DJ; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5620-4. PubMed ID: 21778056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
    Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
    J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.
    Aronov AM; Tang Q; Martinez-Botella G; Bemis GW; Cao J; Chen G; Ewing NP; Ford PJ; Germann UA; Green J; Hale MR; Jacobs M; Janetka JW; Maltais F; Markland W; Namchuk MN; Nanthakumar S; Poondru S; Straub J; ter Haar E; Xie X
    J Med Chem; 2009 Oct; 52(20):6362-8. PubMed ID: 19827834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors.
    Terao Y; Suzuki H; Yoshikawa M; Yashiro H; Takekawa S; Fujitani Y; Okada K; Inoue Y; Yamamoto Y; Nakagawa H; Yao S; Kawamoto T; Uchikawa O
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7326-9. PubMed ID: 23147077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.
    Shim J; Eid C; Lee J; Liu E; Chaudhary D; Boschelli DH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6575-7. PubMed ID: 19854645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
    Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
    Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.